Medicine created by an artificial intelligence will be tested for the first time in humans


A new milestone in artificial intelligence applied to medicine is marked by the discovery of a DSP-1181 molecule developed entirely by an AI.

The new compound, which has been designed to treat patients with obsessive-compulsive disorder, was developed by Exscientia, an Oxford-based artificial intelligence startup, in collaboration with Japanese pharmaceutical company Sumitomo Dainippon Pharma.